AHA Coding Clinic® for HCPCS - 2012 Quarter 2; For Your Information
Drugs and Biologicals with OPPS Pass-Through Status Effective April 1, 2012
CMS has granted pass-through status to four (4) drugs. HCPCS code C9288 , Injection, centruroides (scorpion) immune f(ab)2 (equine), 1 vial, C9289 , Injection, asparaginase erwinia chrysanthemi, 1,000 international units (I.U.), C9290 , Injection, bupivacaine liposome, 1 mg, and C9291 , Injection, aflibercept, 2 mg vial. These codes became effective on April 1, 2012. ...
Subscribe or sign in to view the full article.
Article Overview
This brief CMS update identifies outpatient prospective payment system (OPPS) pass-through status changes for a small set of drugs and biologicals effective in April 2012. It is relevant to hospital outpatient coders, billing staff, and reimbursement teams who track HCPCS updates and CMS payment-status changes.
Why This Topic Matters
Pass-through status changes can affect how outpatient services are reported and reimbursed, so keeping current helps support accurate claims processing and payment analysis.
What You Will Learn
- Which kinds of outpatient drug and biological updates are addressed by the CMS notice.
- How the article frames effective-date information for OPPS-related reporting.
- What general reimbursement update categories are covered in the notice.
- How to recognize the article’s scope as a coding and billing update rather than a clinical discussion.
Who Should Read This
- Hospital outpatient coders
- Billing and reimbursement staff
- Revenue cycle teams
- Compliance staff
- Healthcare coding professionals
Codes Discussed
Subscribe or sign in to view the full article.
Quick, Current, Complete - www.findacode.com